| Literature DB >> 31941771 |
Jérémie Prévost1,2, Cassandra R Edgar3, Jonathan Richard1,2, Steven M Trothen3, Rajesh Abraham Jacob3, Mitchell J Mumby3, Suzanne Pickering4, Mathieu Dubé1, Daniel E Kaufmann1,5, Frank Kirchhoff6, Stuart J D Neil4, Andrés Finzi7,2,8, Jimmy D Dikeakos9.
Abstract
Along with other immune checkpoints, T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) is expressed on exhausted CD4+ and CD8+ T cells and is upregulated on the surface of these cells upon infection by human immunodeficiency virus type 1 (HIV-1). Recent reports have suggested an antiviral role for Tim-3. However, the molecular determinants of HIV-1 which modulate cell surface Tim-3 levels have yet to be determined. Here, we demonstrate that HIV-1 Vpu downregulates Tim-3 from the surface of infected primary CD4+ T cells, thus attenuating HIV-1-induced upregulation of Tim-3. We also provide evidence that the transmembrane domain of Vpu is required for Tim-3 downregulation. Using immunofluorescence microscopy, we determined that Vpu is in close proximity to Tim-3 and alters its subcellular localization by directing it to Rab 5-positive (Rab 5+) vesicles and targeting it for sequestration within the trans- Golgi network (TGN). Intriguingly, Tim-3 knockdown and Tim-3 blockade increased HIV-1 replication in primary CD4+ T cells, thereby suggesting that Tim-3 expression might represent a natural immune mechanism limiting viral spread.IMPORTANCE HIV infection modulates the surface expression of Tim-3, but the molecular determinants remain poorly understood. Here, we show that HIV-1 Vpu downregulates Tim-3 from the surface of infected primary CD4+ T cells through its transmembrane domain and alters its subcellular localization. Tim-3 blockade increases HIV-1 replication, suggesting a potential negative role of this protein in viral spread that is counteracted by Vpu.Entities:
Keywords: HIV; Tim-3; Vpu; membrane trafficking; viral release
Mesh:
Substances:
Year: 2020 PMID: 31941771 PMCID: PMC7081912 DOI: 10.1128/JVI.01999-19
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103